{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-24-000057","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.125996+00:00","generated_at":"2026-06-02T04:02:32.417071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Instil Bio reports Q1 net loss $3.74/share; cash runway beyond 2026","bullets":["Cash, equivalents and investments of $161.5M at March 31, 2024; runway extends beyond 2026.","Net loss per share (GAAP) $3.74 vs $8.77 YoY; non-GAAP loss per share $2.39 vs $4.29.","R&D expenses fell to $7.3M from $20.7M; restructuring/impairment charges dropped to $4.3M.","Preparing potential investigator-initiated trial of FRα-CoStAR TIL in non-small cell lung cancer.","Company is exploring in-licensing or acquiring novel therapeutic candidates for unmet needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-24-000057","json":"https://secwatch.observer/filing/0001789769-24-000057.json","markdown":"https://secwatch.observer/filing/0001789769-24-000057.md","text":"https://secwatch.observer/filing/0001789769-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/0001789769-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/til-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:02:32.417071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fcb0a7e15dc908bd4878dbe0c25d5c4cb8cf3cb","claim":"Instil Bio, Inc. reported the quarter ended March 31, 2024 results: EPS Net loss per share, basic and diluted were $3.74.","evidence_excerpt":"On May 10, 2024 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/0001789769-24-000057-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"EPS","value":"Net loss per share, basic and diluted were $3.74"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}